VERU INC.
VERU evidence brief
What we can confirm
- BioSniper Score:
- 6.2 / 10
- Market Cap:
- $43.3M
- Next Catalyst:
- Phase2_Topline · Mar 31, 2027
What it means
What to watch
Prepared research question
What matters most for VERU—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VERU
VERU INC. is a late clinical-stage biopharmaceutical company developing two novel small molecules, enobosarm and sabizabulin, for cardiometabolic and inflammatory diseases, with a recent strategic expansion into pancreatic cancer [sec_mda · as of 2026-08-10] [sec · filed 2026-09-08].
Key risk: Not profitable, negative cash flow
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 4 clinical trials · 1 catalyst for VERU INC..
VERU INC. is a late clinical-stage biopharmaceutical company developing two novel small molecules, enobosarm and sabizabulin, for cardiometabolic and inflammatory diseases, with a recent strategic expansion into pancreatic cancer [sec_mda · as of 2026-08-10] [sec · filed 2026-09-08].
- Cash and equivalents of $23.9M as of 2026-06-30 [sec].
- Net income of -$7.0M as of 2026-06-30 [sec].
- Shareholders' equity of $28.4M as of 2026-06-30 [sec].
- Phase 2b PLATEAU clinical trial evaluating enobosarm + semaglutide completed enrollment in July 2026 [news · published 2026-07-27].
- Positive preclinical data for sabizabulin in daraxonrasib-resistant pancreatic cancer cell lines reported in September 2026 [sec · filed 2026-09-08].
What works
- Enobosarm targets a large market by aiming to improve body composition and physical function in GLP-1 RA weight reduction therapy [sec_mda · as of 2026-08-10].
- Sabizabulin has shown a good safety profile and promising efficacy in prior clinical studies, including a 55.2% relative reduction in deaths in a COVID-19 trial [catalyst] [news · published 2026-09-08].
- The company has received FDA regulatory clarity for enobosarm in combination with GLP-1 RA, with incremental weight loss as an acceptable primary endpoint [news · published 2025-12-17].
What to weigh
- The company is not profitable and has had negative cash flow from operations [sec_mda · as of 2026-05-13].
- Substantial capital will be needed to support drug development and any related commercialization efforts [sec_mda · as of 2026-05-13].
- The company faces competitive market pressures in the obesity and inflammation spaces [news · published 2026-05-13].
From the filings
Quoted directly from source documents.
Enobosarm development focus
“Enobosarm, an oral selective androgen receptor modulator ("SARM"), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass”
SEC MD&A · August 10, 2026
Sabizabulin preclinical data in pancreatic cancer
“new, positive preclinical data for its oral, novel, microtubule targeting agent, sabizabulin, demonstrating augmented anticancer activity in KRAS -metastatic pancreatic cancer cell lines that were resistant to daraxonrasib”
SEC filings · September 8, 2026
Catalyst timeline
- 2027-03-31 · Phase2_Topline — Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress.
Risks & what to watch (3)›
Key risks
- Not profitable, negative cash flow — The company is not profitable and has had negative cash flow from operations [sec_mda · as of 2026-05-13].
- Need for substantial capital — Substantial capital will be needed to support drug development and commercialization [sec_mda · as of 2026-05-13].
- Competitive market pressures — Faces ongoing financial hurdles and competitive market pressures [news · published 2026-05-13].
What to watch
- Phase 2b PLATEAU clinical trial interim analysis expected in first quarter calendar year 2027 [news · published 2026-05-13].
- Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress on 2027-03-31 [catalyst].
- Potential clinical development of sabizabulin for atherosclerotic cardiovascular disease [sec_mda · as of 2026-08-10].
- Expansion of sabizabulin into pancreatic cancer based on preclinical data [sec · filed 2026-09-08].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run VERU INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available VERU INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.30
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~168d
1 buy · 0 sells (180d)
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
56
Total value held
$7.1M
| Holder | Shares | Value |
|---|---|---|
| alyeska investment group, l.p. | 1,000,000 | $2.2M |
| vanguard capital management llc | 539,382 | $1.2M |
| oppenheimer & co inc | 196,300 | $434K |
| geode capital management, llc | 184,622 | $408K |
| summit financial, llc | 151,783 | $335K |
| millennium management llc | 150,401 | $332K |
| ikarian capital, llc | 133,517 | $295K |
| blackrock, inc. | 114,169 | $252K |
| vanguard fiduciary trust co | 80,653 | $178K |
| choreo, llc | 75,263 | $166K |
Showing top 10 of 56 institutional holders of VERU INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 4.5%
- Days to cover
- 12.4
- Shares short
- 656,045
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VERU short interestGovernance
Frequently asked questions
What is the AI investment thesis for VERU INC.?
VERU INC. is a late clinical-stage biopharmaceutical company developing two novel small molecules, enobosarm and sabizabulin, for cardiometabolic and inflammatory diseases, with a recent strategic expansion into pancreatic cancer [sec_mda · as of 2026-08-10] [sec · filed 2026-09-08].
What is VERU INC.'s next catalyst?
VERU INC.'s next tracked catalyst is a Phase2_Topline event — "Phase2_Topline: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress" — expected March 31, 2027.
Who is the CEO of VERU INC.?
Dr. Mitchell S. Steiner F.A.C.S., M.D. is the chief executive officer of VERU INC. (VERU).
Where is VERU INC. headquartered?
VERU INC. (VERU) is headquartered in Miami, FL, United States.
What therapeutic areas does VERU INC. focus on?
VERU INC. develops therapies across Infectious Disease, Metabolic, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.